System C: Potential Acquirers

Nelson Advisors
5 hours ago
12 min read

The proposed sale of System C Healthcare by CVC Capital Partners, currently facilitated by the corporate finance advisory firm Arma Partners, marks a defining transaction in the mid-decade consolidation of the United Kingdom’s health and social care technology sectors. The asset, held under the parent entity Asclepius Topco Limited, has undergone a fundamental transformation since its acquisition from Symphony Technology Group in February 2021.

At that time, the business was valued at an enterprise value exceeding 20x EV/EBITDA based on a trailing EBITDA of approximately £12 million. By the 2026 fiscal year, System C is projected to deliver an EBITDA of £46 million, reflecting a nearly four-fold increase in profitability under CVC’s stewardship based on a recent Mergermarket report. This trajectory is not merely a result of organic growth but is the culmination of a sophisticated "buy-and-build" strategy that has integrated specialised clinical capabilities in oncology, maternity and medicines management with a dominant market share in the social care and education software verticals.

The divestiture process comes at a time when the UK’s National Health Service (NHS) is transitioning from its initial "Frontline Digitisation" phase toward an era of integrated care and "ambient" artificial intelligence. The market for Electronic Patient Records (EPR) has largely matured, with 97% of acute trusts in England expected to have a system in place by March 2026. Consequently, the value proposition for System C has shifted from being a provider of record-keeping software to a strategic data platform that bridges the traditionally siloed environments of acute hospitals and community based social care.

This report explores the financial architecture of the transaction, the competitive landscape involving Oracle Health and Epic Systems, the strategic rationale for international expansion via the Australian provider MYP Technologies and the profiling of likely strategic and private equity acquirers in a market defined by high-recurring-revenue SaaS models and AI-driven efficiency mandates.

Financial Architecture and Valuation Modelling in the 2026 Exit Environment

The financial performance of System C under CVC’s ownership provides a case study in margin expansion through vertical specialisation and technological modernisation. Financial filings for Asclepius Topco Limited show revenues of £107.2 million for the year ending March 31st, 2025. When viewed alongside the projected £46 million EBITDA for FY26, the company exhibits an EBITDA margin approaching 43%, a premium profile that reflects the high scalability of its cloud-native CareFlow and LiquidLogic platforms.

The Evolution of Valuation Multiples

The 2021 acquisition multiple of 20x EV/EBITDA was considered aggressive at the time, yet it was anchored in the mission-critical nature of the software and the low churn rates inherent in government-funded healthcare contracts. As Arma Partners brings the asset to market in 2026, the valuation will be judged against a higher EBITDA base but within a macroeconomic environment characterised by more disciplined capital allocation and a focus on "profitable efficiency".

The resilience of data-driven businesses in the face of generative AI advancements, a trend highlighted by Arma Partners' own research, supports the maintenance of a premium multiple, as these platforms control the primary data sources required for AI implementation.

Financial Metric	FY2021 (Acquisition)	FY2025 (Reported)	FY2026 (Projected)
Revenue	~£80 million	£107.2 million	~£130 million (estimated)
EBITDA	£12 - £15 million	~£38 million (est.)	£46 million (reported by Mergermarket)
EBITDA Margin	15% - 18.7%	~35.4%	~35.4% - 43%
Implied EV (at 20x)	£240 - £300 million	N/A	£920 million

Source: Mergermarket, 23rd Apr 2026, 'System C owner CVC appoints Arma Partners for sale ofhealthcare software firm'

Revenue Quality and Retention Metrics

A critical component of the valuation will be the quality of the recurring revenue. In the 2026 market, buyers are increasingly separating software acquisition costs from the total cost of transformation, including data remediation and adoption. System C’s revenue is characterised by:

High Recurring Revenue Rate: Estimated at over 90%, consistent with leading peers like The Access Group and Dedalus.
Low Customer Churn: Mission-critical EPR and social care systems typically experience churn rates below 2%, as the cost and clinical risk of replacement are prohibitive.
Expansion Revenue: The ability to upsell modules such as the "FormFlow AI Assistant" to an existing base of 40 NHS hospitals and 60% of English councils.

The integration of MYP Technologies in August 2025 adds an international dimension to the revenue profile. While the absolute revenue contribution of the Australian entity is smaller than the UK core, its role as a beachhead in the APAC region and a provider of 24/7 support capabilities enhances the "global platform" narrative, which typically commands a 2x to 3x turn multiple premium over domestic-only players.

Product Ecosystem: Bridging the Acute-Social Care Divide

System C’s competitive moat is built upon its "joined-up" digital strategy. While many competitors focus exclusively on the acute hospital environment, System C has built a dominant presence in the "back-office" and community sectors, which are increasingly recognised as the primary bottlenecks for healthcare efficiency.

CareFlow: The Clinical and Acute Backbone

The CareFlow EPR suite represents a modernized evolution of the legacy Medway system. It encompasses electronic patient records, patient flow management, and clinical communication. In 2026, the focus of CareFlow has shifted toward "ambient" clinical documentation.

The acquisition of FormFlow AI has allowed System C to embed AI-driven assistants that help clinicians automate the recording of patient encounters, a move that directly addresses the 98% of social care professionals who identified administrative burden as a primary obstacle to care.

The clinical depth of the CareFlow suite is further evidenced by its market leadership in specialised areas:

Oncology: Through CIS Oncology, System C manages complex chemotherapy protocols for 80% of the UK market.
Maternity: The BadgerNet platform provides a national contract in several regions, including New Zealand, ensuring that the company is deeply embedded in specialized clinical workflows that are difficult for "generalist" EPRs like Epic or Oracle to displace.
Medicines Management: Managing over £9 billion in medications annually provides System C with a massive repository of prescribing data, which is a key asset for population health analytics and value-based procurement.

Liquidlogic and the Social Care Nexus

System C’s acquisition of Liquidlogic in 2009 was a visionary move that anticipated the current drive toward integrated care. Liquidlogic is now the market-leading solution for children’s and adults' social care in England. The strategic relevance of this cannot be overstated: as Integrated Care Systems (ICS) in England seek to manage "bed-blocking" and delayed discharges, the ability to have hospital systems (CareFlow) talk seamlessly to social care systems (Liquidlogic) becomes a "golden ticket" for operational efficiency.

International Expansion and the MYP Technologies Acquisition

The August 2025 acquisition of Australian peer MYP Technologies serves two primary strategic goals. First, it diversifies the company’s revenue away from the UK’s single-payer risk. Second, it brings specialised community-based and aged care management tech into the portfolio. MYP’s solutions are purpose-built for disability, allied health and aged care sectors that are seeing significant funding increases in Australia ($3 billion commitments) and Europe.

Acquisition Target	Date	Strategic Value
Liquidlogic	2009	Established 60% market share in UK social care.
OCC	2023	Added integrated contracts and finance solutions for local government.
CIS Oncology	2024	Secured 80% of the UK oncology software market.
MYP Technologies	Aug 2025	Internationalized the platform; added 24/7 global support.

The Competitive Landscape: Consolidation and Challenger Dynamics

The 2026 UK healthcare IT market is defined by a paradox: while most acute trusts have chosen an EPR, the market remains highly competitive as trusts look for "replacement" systems that offer better interoperability and lower total cost of ownership.

The Oracle Health (Cerner) and Epic Dominance

Oracle Health (formerly Cerner) remains the market leader in the UK, with approximately 25% of the acute EPR market. However, the company has faced significant headwinds. Oracle’s massive $28.3 billion acquisition of Cerner in 2022 has been followed by reports of financial strain, leading to rumors of a potential divestiture of the unit in 2026 to fund its $156 billion AI infrastructure commitments.

Furthermore, Oracle executed significant layoffs on March 31, 2026, cutting an estimated 30% of its Revenue and Health Sciences division. This "talent window" has allowed competitors like System C and Nervecentre to poach experienced EHR specialists and implementation engineers.

Epic Systems, by contrast, has seen the biggest gains in market share, rising to 9.7% of the UK market by 2025. Epic’s strategy focuses on "mega-trusts" and regional clusters, such as the £222 million contract for Somerset and Dorset. While Epic dominates the high end of the market, its high implementation costs and "closed ecosystem" perception leave significant room for more agile, cloud-native providers like System C.

The Rise of Nervecentre

Nervecentre has emerged as the fastest-growing EPR provider in the UK, recently becoming the second-largest supplier by hospital bed count. Nervecentre’s cloud-native platform is being adopted across regional clusters like Liverpool and the East Midlands, emphasising a "shared foundation" for regional transformation. The success of Nervecentre validates the market's appetite for SaaS-based, intuitive tools, a segment where System C’s CareFlow suite is also strongly positioned.

Dedalus and the European Deleveraging

Dedalus Group, once a dominant force in European health software, has focused on deleveraging and improving profitability in 2025 and 2026. With a market-leading position in DACH and Southern Europe, Dedalus is a formidable peer, but its "no acquisitions" stance through 2026, required to bring leverage down toward 8x EBITDA, effectively removes it as a likely bidder for System C.

Strategic Acquirer Profiling: Who Will Buy System C?

The "fireside chats" led by Arma Partners are likely engaging a mix of domestic strategic players, US based consolidators, and large-scale private equity firms.

1. The Access Group

The Access Group is perhaps the most logical strategic acquirer. With a valuation of over £9 billion and a mission focused on "empowering ambitious organisations" through cloud solutions, Access has a proven playbook for rapid M&A integration, having completed over 40 acquisitions in recent years.

Strategic Fit: Access is heavily focused on HR, payroll, and ERP, but its "Access Care & Clinical" solution for social care is a direct adjacency to System C’s Liquidlogic.
The AI Angle: Access is aggressively rolling out its "Access Evo" AI platform. System C’s clinical and social care data would provide the essential training sets for Access to become a dominant AI player in the UK public sector.

2. IRIS Software Group

IRIS Software Group has evolved from a specialist in accountancy and payroll into a diversified provider of mission-critical software for the public sector.

Strategic Fit: IRIS already manages over 1,000,000 staff globally and pays one in six UK workers. Its specialised "IRIS GP Payroll" and accountancy software for healthcare organisations provide a natural "front-door" into the GP surgeries that must integrate with System C’s hospital and social care records.
Consolidation Rationale: Acquiring System C would allow IRIS to bridge the gap between back-office financial management and front-line clinical delivery, creating a "total workforce and care management" platform.

3. Civica

Civica is a UK-based public sector specialist that has historically grown through niche acquisitions like InfoFlex.

Strategic Fit: Civica’s strength in local government and its existing presence in the health sector make it a natural contender. A merger with System C would create a "UK National Champion" in public service software, providing the scale needed to compete with US hyperscalers.

4. US-Based Hyperscalers and Strategic Bidders (Oracle, Microsoft, Amazon)

While less likely to be direct bidders for a UK-centric asset, these firms influence the valuation ceiling:

Oracle: If Oracle divests Cerner, it may ironically look to "buy back" into the UK market with a cleaner, more profitable asset like System C once its balance sheet is repaired.
Microsoft: Operates as a "neutral infrastructure" layer via Azure and Nuance (DAX Copilot). An acquisition would jeopardise its status as the preferred partner for Epic and Meditech.
Altera Digital Health: As a business unit of the "serial acquirer" Harris Healthcare, Altera has the mandate to grow its UK presence. A combination of Altera’s Sunrise EPR and System C’s Liquidlogic would create a highly diversified, "permanent home" for clinical tech.

5. Private Equity (Thoma Bravo, Francisco Partners, Bain Capital)

These firms enter 2026 with an estimated $2.5 trillion in unallocated capital. Their strategy is the "Buy and Build" model, acquiring a mature platform like System C and then bolting on dozens of small, regional "TechBio" or RCM (Revenue Cycle Management) providers. System C, with its £46 million EBITDA, is at the ideal "platform" size for a large-scale PE exit.

Market Drivers and Regulatory Headwinds: The 2026 Context

The valuation of System C is fundamentally linked to the structural shifts within the NHS and the broader UK regulatory environment.

The NHS 10-Year Plan and the "Left Shift"

The UK’s health strategy is defined by the "Left Shift", moving care away from expensive hospital settings and into the community and the home. This shift directly benefits System C’s social care and community-focused portfolio (Liquidlogic and MYP). Technologies that facilitate remote patient monitoring (RPM) and community diagnostics are seeing faster adoption than traditional hospital-only tools

Value-Based Procurement and Clinical Validation

Starting in early 2026, the NHS has enforced standardized "value-based procurement" guidance. This means that procurement decisions are no longer based on the "cheapest price" but on evidence of long-term patient outcomes and total pathway cost savings. System C’s deep clinical modules in oncology and maternity, which track outcomes over many years, provide the "clinical validation" that generic EPRs lack, making it a more resilient asset in a value-based market.

The EHDS and the EU AI Act

For international bidders, System C’s compliance with the European Health Data Space (EHDS) and the EU AI Act is a major selling point. The high cost of compliance with these regulations makes it difficult for new entrants to penetrate the European market, thereby increasing the scarcity value of established, compliant platforms like System C.

The "EPR" Confusion: Packaging vs. Records

A unique contextual factor in the 2026 market is the rollout of the "Extended Producer Responsibility" (EPR) for packaging in the UK. While this is a waste management regulation, it has created a broader demand for "traceability software" across all sectors, including healthcare. Companies like SAP and Workday are integrating these "packaging EPR" modules into their core platforms. A strategic acquirer from the ERP space might view System C as the "missing link" to provide total traceability for medical supplies and patient records in a unified system.

Australia and New Zealand: The APAC Strategic Beachhead

The acquisition of MYP Technologies is a response to the "Supply Gap" in the global health workforce. By 2030, the global healthcare workforce shortage is predicted to reach 11 million workers. Australia and New Zealand, with their aging populations and high healthcare spend, are key markets for automation technologies.

Country	Key Public Funding Commitment (2022-2025)	Market Opportunity
UK	~£9B (2025) for health/social care	Integrated care and Frontline Digitisation.
Australia	~A$3B (2022) for disability/aged care	Community-based care and NDIS support.
European Union	~€1.5B (2022) for digital health	EHDS compliance and cross-border data.

System C's presence in Australia, where it already holds national maternity and child protection contracts, allows it to offer a "global support model". For a US-based acquirer, this provides an immediate, ready-made international expansion vehicle that has already cleared the cultural and regulatory hurdles of the APAC region.

Synthesis: The Value Proposition for an Acquirer

The sale of System C is not merely the divestiture of a software company; it is the transfer of a strategic infrastructure asset that sits at the center of the UK’s integrated care ambitions. The value proposition for an acquirer is built on three recursive layers of value:

Layer 1: The Defensive Core

A highly profitable (£46M EBITDA), high-margin (~40%), and low-churn software business with a 90%+ recurring revenue rate. The mission-critical nature of the EPR and social care records ensures that cash flows are protected even in a downturn.

Layer 2: The Synergistic Platform

The unique "Acute + Social Care" combination. An acquirer like The Access Group or IRIS can leverage System C’s dominance in local government (60% share) to cross-sell a wide range of HR, payroll, and financial software. For an ICS, the "joined-up" record is a primary driver of cost savings, making System C the preferred partner for regional transformation.

Layer 3: The AI and International Upside

The potential to use System C’s massive, longitudinal data sets (oncology, maternity, medications) to train the next generation of "ambient clinical intelligence". The APAC presence via MYP Technologies provides the "exit ramp" for future growth beyond the UK, justifying a premium multiple in the 18x-22x range.

Conclusions and Strategic Outlook

As Arma Partners proceeds with the sale of System C, the transaction is expected to be one of the largest in the UK health-tech space in 2026. The projected enterprise value likely sits between £750 million and £900 Million, representing a significant return for CVC Capital Partners on their 2021 investment.

The eventual winner of the process will likely be the firm that can best articulate a vision for "Total Integrated Care", one that utilises System C’s data richness to solve the systemic issues of workforce shortages and delayed hospital discharges.While private equity firms remain the most active buyers in the sub-£50m deal bracket, the scale and strategic importance of System C suggest that a large-scale strategic consolidator or a "mega-PE" fund looking for a platform for a global roll-up is the most probable outcome.

Ultimately, the System C divestiture reflects a broader trend: in the 2026 health-tech market, the value has shifted from the software to the data and the workflow. The companies that control the clinical and social care record are the ones that will define the efficiency of the healthcare systems of the next decade. System C, with its unique vertical dominance and international footprint, is positioned at the very heart of this transformation.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech